| P2093 | author name string | Eric G Boyce | |
| | Susan P Bruce | |
| P2860 | cites work | Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells | Q36368842 |
| | Methotrexate pharmacogenomics | Q36564583 |
| | Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases | Q42099549 |
| | Ulcerative colitis during CTLA-4Ig therapy in a patient with rheumatoid arthritis | Q42844399 |
| | Agreement of Mexican rheumatologists with the ASsessment in Ankylosing Spondylitis International Working Group and the EUropean League Against Rheumatism recommendations for the management of ankylosing spondylitis | Q42955475 |
| | Lack of association of mannose binding lectin variant alleles with systemic lupus erythematosus | Q42956271 |
| | Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study | Q44464975 |
| | Structural progression is also driven by clinical symptoms in patients with osteoarthritis | Q44727904 |
| | American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis | Q47643186 |
| | Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. | Q53239672 |
| | Treatment of rheumatoid arthritis | Q56060521 |
| | Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion | Q56904375 |
| | Cytokine pathways and joint inflammation in rheumatoid arthritis | Q33939087 |
| | Pathogenesis of rheumatoid arthritis. The role of T cells and other beasts. | Q34275978 |
| | Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial | Q34559671 |
| | Appropriate and effective management of rheumatoid arthritis | Q35554231 |
| | Assessment of the clinical significance of gelatinase activity in patients with juvenile idiopathic arthritis using quantitative protein substrate zymography | Q35637026 |
| | Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial | Q35638718 |
| | Toward a better understanding of methotrexate | Q35775065 |
| | New drugs for rheumatoid arthritis | Q35777601 |
| | Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis | Q35789095 |
| | Emerging biological therapies in rheumatoid arthritis | Q35979143 |
| | Rheumatoid arthritis: an overview of new and emerging therapies | Q36160669 |
| | Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis | Q36343473 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P1104 | number of pages | 10 | |
| P304 | page(s) | 1153-1162 | |
| P577 | publication date | 2007-07-03 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Update on abatacept: a selective costimulation modulator for rheumatoid arthritis | |
| P478 | volume | 41 | |